Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, Salt Lake City, UT 84112, USA; Department of Oncological Sciences, University of Utah, 2000 Circle of Hope, Salt Lake City, UT 84112, USA.
Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, Salt Lake City, UT 84112, USA; Department of Surgery, University of Utah, 30 N 1900 E, Salt Lake City, UT 84132, USA.
STAR Protoc. 2023 Sep 15;4(3):102402. doi: 10.1016/j.xpro.2023.102402. Epub 2023 Jul 3.
Patient-derived xenografts (PDXs) have clinical value but are time-, cost-, and labor-intensive and thus ill-suited for large-scale experiments. Here, we present a protocol to convert PDX tumors into PDxOs for long-term cultures amenable to moderate-throughput drug screens, including in-depth PDxO validation. We describe steps for PDxO preparation and mouse cell removal. We then detail PDxO validation and characterization and drug response assay. Our PDxO drug screening platform can predict therapy response in vivo and inform functional precision oncology for patients. For complete details on the use and execution of this protocol, please refer to Guillen et al..
患者来源异种移植物（PDX）具有临床价值，但耗时、耗力且成本高昂，因此不适合大规模实验。在这里，我们提出了一种将 PDX 肿瘤转化为 PDxO 的方案，用于长期培养，可进行中等通量的药物筛选，包括深入的 PDxO 验证。我们描述了 PDxO 制备和去除小鼠细胞的步骤。然后，我们详细介绍了 PDxO 的验证和特征描述以及药物反应测定。我们的 PDxO 药物筛选平台可以预测体内治疗反应，并为患者提供功能精准肿瘤学信息。有关该方案使用和实施的完整详细信息，请参阅 Guillen 等人的研究。
